Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adults and Children with Allergic Rhinoconjunctivitis (ARC) | Adults and children with ARC who complete the survey |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC) | Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated. | Within 12 months prior to survey |
| Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months | Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated. | Within 12 months prior to survey |
| Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months | Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated. | Within 12 months prior to survey |
| Percentage of Participants Who Received Immunotherapy to Treat ARC | Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated. | Within 12 months prior to survey |
| Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication | Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma | Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated. | Within 12 months prior to survey |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults and children with ARC in the United States.
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24679733 | Result | Blaiss MS, Dykewicz MS, Skoner DP, Smith N, Leatherman B, Craig TJ, Bielory L, Walstein N, Allen-Ramey F. Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol. 2014 Apr;112(4):322-8.e1. doi: 10.1016/j.anai.2014.02.006. |
Not provided
Not provided
Not provided
A national probablility sample of 2765 adults & children (age 5+) who had ever been diagnosed with hay fever, allergic rhinitis, rhinoconjunctivitis, nasal allergies or eye allergies & had nasal allergy symptoms in the past 12 months or had taken prescription medicine for allergies were interviewed by telephone about their condition & treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Adults and Children With Allergic Rhinoconjunctivitis (ARC) | Adults and children with ARC who complete the survey |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Adults and Children With ARC | Adults and children with ARC who complete the survey |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC) | Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated. | The analysis population consisted of all participants who responded to the survey. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
Not provided
No formal reporting or recording of adverse events was conducted during this observational study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Adults and Children With ARC | Adults and children with ARC who complete the survey |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D006967 | Hypersensitivity |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Within 12 months prior to survey |
| participants |
|
| Sex/Gender, Customized | Number | participants |
|
| Participants |
|
|
| Primary | Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months | Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated. | The analysis population consisted of all participants who responded to the survey. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
|
| Primary | Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months | Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated. | The analysis population consisted of all participants who responded to the survey. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
|
| Primary | Percentage of Participants Who Received Immunotherapy to Treat ARC | Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated. | The analysis population consisted of all participants who responded to the survey. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
|
| Primary | Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication | Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated. | The analysis population consisted of all participants who responded to the survey, received immunotherapy (allergy shots) and had not taken over-the-counter allergy medication. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
|
| Secondary | Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma | Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated. | The analysis population consisted of all participants who responded to the survey and received allergy shots. | Posted | Number | percentage of participants | Within 12 months prior to survey |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
Not provided
Not provided